Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension

Rhea-AI Summary

Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announces the dosing of the first subject in the Launch-HTN pivotal trial to evaluate the safety and efficacy of lorundrostat for the treatment of uncontrolled or resistant hypertension. The company expects to release topline data from the confirmatory Launch-HTN trial in the second half of 2025 and from the ongoing Advance-HTN pivotal trial in the second half of 2024.

Insights

Medical Research Analyst

The initiation of the Launch-HTN trial by Mineralys Therapeutics represents a significant milestone in the development of lorundrostat for the treatment of uncontrolled and resistant hypertension. This development is particularly noteworthy for stakeholders due to the potential market impact of a successful treatment option in a domain with high unmet medical needs. Hypertension affects a large patient population globally and the introduction of an effective and safe add-on therapy could lead to substantial revenue streams for the company.

Financial Analyst: From a financial perspective, the advancement of lorundrostat into later-stage trials may be a positive indicator for investors, as it suggests progress towards potential commercialization. The announcement of topline data from the Advance-HTN trial in the second half of 2024, followed by the Launch-HTN trial in the second half of 2025, will be closely watched by the market for their implications on the company's valuation. The success of these trials could lead to an increase in stock price and investor confidence, given the size of the hypertension market and the demand for novel treatments.

Industry Analyst: The clinical trial design, a randomized, double-blinded, placebo-controlled Phase 3 trial, aligns with the gold standard for determining drug efficacy and safety. The primary endpoint, change from baseline in systolic blood pressure, is a direct measure of the drug's impact on hypertension, which is a core concern for regulatory approval and market acceptance. If the trials demonstrate significant improvements in blood pressure with a favorable safety profile, lorundrostat could become a key player in the hypertension treatment landscape, potentially disrupting current treatment protocols.

– Topline data from confirmatory Launch-HTN trial expected in 2H 2025 –

– Topline data from ongoing Advance-HTN pivotal trial expected in 2H 2024 –

RADNOR, Pa., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that the first subject has been dosed in the Launch-HTN (NCT06153693) pivotal trial to evaluate the safety and efficacy of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), when used as an add-on therapy to prescribed background treatment.

“Initiating this second pivotal trial demonstrates the continued progress we’re making towards introducing a targeted approach to care in hypertension by identifying and profiling potential responders to lorundrostat,” stated Jon Congleton, Chief Executive Officer of Mineralys. “In parallel with our development of lorundrostat, we have been pleased to see accumulating evidence generated by the medical community highlighting aldosterone as a key driver in cardiorenal disease.”

Launch-HTN is the second of two clinical trials under the planned pivotal program to evaluate the safety and efficacy of lorundrostat when added to subjects’ existing background hypertension treatment. This trial is designed to model real world treatment of uHTN and rHTN in the primary care setting. Launch-HTN is a global, randomized, double-blinded, placebo-controlled Phase 3 trial that is designed to enroll up to approximately 1,000 eligible adult participants who are failing to achieve their blood pressure goal on two to five background antihypertensive medications. Eligible subjects will be randomized to one of three arms: placebo, lorundrostat 50 mg once daily (QD), and lorundrostat 50 mg QD and then titrated to 100 mg QD, as needed, at week six. The primary endpoint of the trial is change from baseline in systolic blood pressure versus placebo after 12 weeks of treatment, as measured by automated office blood pressure monitoring.

Previously, in May 2023, the Company announced the first subject dosed in the first pivotal trial, Advance-HTN. The Company expects to announce topline data from the Advance-HTN trial in the second half of 2024. Subjects in both the Advance-HTN and Launch-HTN trials are provided the opportunity to participate in the open-label extension trial, Transform-HTN.

About Hypertension
Having sustained, elevated blood pressure (or hypertension) increases the risk of heart disease, heart attack and stroke, which are leading causes of death in the U.S. In 2020, more than 670,000 deaths in the U.S. included hypertension as a primary or contributing cause. Hypertension and related health issues resulted in an average annual economic burden of about $130 billion each year in the U.S., averaged over 12 years from 2003 to 2014.

Less than 50% of hypertension patients achieve their blood pressure goal with currently available medications. Abnormally elevated aldosterone levels are a key factor in driving hypertension in approximately 25% of all hypertensive patients.

About Lorundrostat
Lorundrostat is a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled and resistant hypertension and CKD. Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production. Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro, an observed half-life of 10-12 hours and demonstrated approximately a 70% reduction in plasma aldosterone concentration in hypertensive subjects.

About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD and other diseases driven by abnormally elevated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and CKD. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.

Forward-Looking Statements
Mineralys Therapeutics cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to, statements regarding: the potential therapeutic benefits of lorundrostat; the Company’s expectation that aldosterone synthase inhibitors with an SGLT2 inhibitor may provide additive clinical benefits to patients; the Company’s expectation that the Advance-HTN and the planned Phase 3 clinical trial of lorundrostat may serve as pivotal trials in any submission of a new drug application (NDA) to the United States Food and Drug Administration (FDA); the Company’s ability to evaluate lorundrostat as a potential treatment for CKD or uncontrolled hypertension; the planned future clinical development of lorundrostat and the timing thereof; and the expected timing of commencement and enrollment of patients in clinical trials and topline results from clinical trials. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: our future performance is dependent entirely on the success of lorundrostat; potential delays in the commencement, enrollment and completion of clinical trials and nonclinical studies; later developments with the FDA may be inconsistent with the feedback from the completed end of Phase 2 meeting, including whether the proposed pivotal program will support registration of lorundrostat which is a review issue with the FDA upon submission of an NDA; our dependence on third parties in connection with manufacturing, research and clinical and nonclinical testing; unexpected adverse side effects or inadequate efficacy of lorundrostat that may limit its development, regulatory approval and/or commercialization; unfavorable results from clinical trials and nonclinical studies; results of prior clinical trials and studies of lorundrostat are not necessarily predictive of future results; our ability to maintain undisrupted business operations due to any pandemic or future public health concerns; regulatory developments in the United States and foreign countries; our reliance on our exclusive license with Mitsubishi Tanabe Pharma to provide us with intellectual property rights to develop and commercialize lorundrostat; and other risks described in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contact:
Investor Relations
investorrelations@mineralystx.com

Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com

FAQ

What is the purpose of the Launch-HTN trial by Mineralys Therapeutics, Inc. (Nasdaq: MLYS)?

The purpose of the Launch-HTN trial is to evaluate the safety and efficacy of lorundrostat for the treatment of uncontrolled or resistant hypertension in adult participants.

What is the primary endpoint of the Launch-HTN trial?

The primary endpoint of the trial is the change from baseline in systolic blood pressure versus placebo after 12 weeks of treatment, as measured by automated office blood pressure monitoring.

When is Mineralys Therapeutics, Inc. (Nasdaq: MLYS) expected to release topline data from the Advance-HTN trial?

The company expects to announce topline data from the Advance-HTN trial in the second half of 2024.

What is the focus of Mineralys Therapeutics, Inc. (Nasdaq: MLYS) as a clinical-stage biopharmaceutical company?

Mineralys Therapeutics, Inc. is focused on developing medicines to target hypertension, chronic kidney disease (CKD), and other diseases driven by abnormally elevated aldosterone.